Sales of Taxol and Genexol, which contain paclitaxel, rose together in 1H this year. After the sales companies for the two drugs were switched, competition between Boryeong, which has Taxol, and HK Inno.N, which owns Genexol, have been intensifying.

According to the industry research institution IQVIA on the 30th, Taxol posted sales of KRW 5.1 billion 1H this year. This is a 29% YoY increase from the KRW 3.9 billion it had made in 1H last year.

Taxol is a cytotoxic anticancer drug that contains paclitaxel. It is widely used for various types of cancers including ovarian cancer, breast cancer, lung cancer, and gastric cancer. It is still widely used even 30 years after its approva